CURRICULUM VITAE

Updated on Jan. 16th, 2016

Yu-Lin Lin M.D., Ph.D.

Dr. Lin is a well-experienced medical oncologist and a faculty at Department of Oncology in National Taiwan University Hospital (NTUH) in Taiwan. He earned his M.D. degree at College of Medicine in Chung Shan Medical University in 1999. After that, he moved to NTUH to have his residency training in the Department of Internal Medicine and fellowship training in the Department of Oncology during 1999-2005. He has worked as a faculty at Department of Oncology in NTUH since 2005.

He later received further advanced research training at Department of Medicinal Chemistry in College of Pharmacy of Ohio State University (OSU) in U.S.A. in 2007. During the same period of time, he was also an observer at Phase I clinical trial center and Division of Hematology and Oncology in Department of Internal Medicine in OSU Comprehensive Cancer Center in U.S.A. He then came back to Taiwan and has earned his Ph.D. degree at Institute of Clinical Medicine in College of Medicine of National Taiwan University in 2014. He has been a clinical assistant professor at the Graduate Institute of Clinical Oncology in National Taiwan University college of Medicine since 2016. He has published several basic researches and clinical studies including one in Lancet Oncology as attached below.

Dr. Lin’s specialties are in gastrointestinal cancers (especially in colorectal cancer) and lung cancer. His research interests focus on tumor biology, molecular biology and signal transduction of cancers as well as therapeutic development among cancers. He also conducts and runs clinical trials in NTUH. He has been invited as a speaker in many nationwide scientific meetings and also reviewer for academic journals.

1

PERSONAL INFORMATION Birth Date and Place: Jan. 22, 1974; Tainan, TAIWANSex: MaleCitizenship: TAIWANWork Address: Department of Oncology

National Taiwan University HospitalNo. 7, Chung-Shan South RoadTaipei 100886-2-2312-3456 Ext 67513

E-Mail linyulin@ntu.edu.tw

EDUCATIONJuly 1992 - June 1999Department of Medicine, College of MedicineChung Shan Medical University, Taichung, TaiwanM. D. degree received in June 1999

July 2008-Oct. 2014Graduate Institute of Clinical Medicine, College of Medicine,National Taiwan University, Taipei, TaiwanPh.D. degree earned in Oct. 2014

WORK EXPERIENCEInternal Medicine Resident July 2000 - June 2003National Taiwan University Hospital

Oncology Chief Resident and fellow July 2003 – June 2005National Taiwan University Hospital

Oncology Attending Physician July 2005 – presentNational Taiwan University Hospital

Visiting Scholar Jan. 2007 - Dec 2007 Department of Medicinal Chemistry

College of Pharmacy

2

Ohio State University, OH, U.S.A

Clinical fellow in Phase I clinical trial center Jan. 2007 – Dec. 2007Division of Hematology and OncologyDepartment of Internal Medicine Ohio State University Comprehensive Cancer Center, OH, U.S.A

ACADEMIC APPOINTMENTS Clinical Assistant Professor Feb, 2016 - present Graduate Institute of Oncology,

College of Medicine, National Taiwan University

BOARD CERTIFICATIONS Internal Medicine, TAIWAN, 2003 Medical oncology, TAIWAN, 2005

SOCIETY MEMBERSHIPS Society of Internal Medicine of Taiwan The Chinese Oncology Society

American Society of Clinical Oncology (ASCO)

PUBLICATIONS

1. Lin YL , Chung CY, Chang CS, Wu JS, Kuo KT, Kuo SH, Cheng AL: Prognostic Factors in Extrapulmonary Small Cell Carcinomas. A Large Retrospective Study. Oncology. 2007 Dec 20;72(3-4):181-187

2. Lee JH, Yu CJ, Chen KY, Shih JY, Lin YL, Yang CH. Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer. J Formos Med Assoc. 2010 May;109(5):338-44

3. Lin YL , Yeh KH, Cheng AL. Recent Advances in the Treatment of Metastatic Colorectal Cancer in Taiwan. J Formos Med Assoc. 2011 Jan;110(1):1-3

4. Ch’ang HJ, Lin YL (co-first author) , Wang HP, Chiu YF, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin PW, Shan YS, Cheng AL, Chang JY, Hwang TS, Chen LT. Induction Chemotherapy with Gemcitabine, Oxaliplatin and 5-Fluorouracil/ Leucovorin Followed by Concomitant Chemoradiation in Patients

3

with Locally Advanced Pancreatic Cancer: A Taiwan Cooperative Oncology Group Phase II Study. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e749-57. Epub 2011 Mar 21 (impact factor: 4.5)

5. Liang YH, Kuo SW, Lin YL ( correspond ing author) , Chang YL. Disseminated microvascular pulmonary tumor embolism from non-small cell lung cancer leading to pulmonary hypertension followed by sudden cardiac arrest. Lung Cancer. 2011 Apr;72(1):132-5. Epub 2011 Feb 17.

6. Lin YL, Liang JT. FOLFOX4 in the Adjuvant Treatment of Colon Cancer in Asian Patients. Hepatogastroenterology. 2012 Mar-Apr;59(114):400-4

7. Liao WC, Wang HP, Huang HY, Wu MS, Chiang H, Tien YW, Lin YL, Lin JT. CXCR4 Expression Predicts Early Liver Recurrence and Poor Survival after Resection of Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2012 Sep 13;3:e22. doi: 10.1038/ctg.2012.18

8. Lu LC, Shao YY, Hsu CH, Hsu C, Cheng WF, Lin YL , Cheng AL, Yeh KH. Metastasectomy of Krukenberg Tumors May Be Associated with Survival Benefits in Patients with Metastatic Gastric Cancer. Anticancer Research. 2012, 32: 3397-3402

9. Lin YL , Liau JY, Yu SC, Lin LI, Tseng LH, Chang YL, Yeh KH, Cheng AL. KRAS Mutation is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells. PLoS One. 2012;7(11):e50701. doi: 10.1371/journal.pone.0050701. Epub 2012 Nov 28 (5-year impact factor: 4.61)

10. Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL , Lin MY A, Yang CH. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol. 2013;7(1):112-20. (Impact factor: 6.7)

11. Lin YL , Liau JY, Yu SC, Tseng LH, Lin LI, Liang JT, Lin BR, Hung JS, Chang YL, Yeh KH, Cheng AL. Oxaliplatin-Based Chemotherapy Regimens in KRAS Mutant Metastatic Colorectal Cancer Result in Longer Progression-Free Survival than in KRAS Wild-Type Metastatic Colorectal Cancer. Transl Oncol. 2013;6 (3):363-9. (impact factor: 3.39)

12. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL , Dito E, Ong A, Wang YW, Yeh GC, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabinerefractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20;109(4):920-5 (impact factor: 5.08)

13. Liao WC, Tu YK, Lin YL, Wu MS, Lin JT, Wang HP, Chien KL. Adjuvant Therapies for Resected Pancreatic Adenocarcinoma: A Systematic Review and Network Meta-analysis. Lancet Oncol. 2013;14:1095-103 (Impact factor: 25.1). Total citation count computed by google: 24

4

14. Lin YL , Liang YH, Tsai JH, Liau JY, Liang JT, Lin BR, Hung JS, Lin LI, Tseng LH, Chang YL, Yeh KH, Cheng AL. Oxaliplatin-Based Chemotherapy is More Beneficial in KRAS Mutant mCRC Patients than in KRAS Wild-Type mCRC Patients. PLoS One. 2014 Feb 4;9(2):e86789 (5-year impact factor: 4.24)

15. Tsai JH, Liau JY, Lin YL, Lin LI, Cheng YC, Cheng ML, Jeng YM. Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis. Mod Pathol. 2014 Oct;27(10):1375-85. IF=6.364; 5/76 Pathology

16. Shen YC, Li CP, Yen CJ, Hsu C, Lin YL, Lin ZZ, Chen LT, Su WC, Chao Y, K. H. Yeh KH, Cheng AL. Phase II Multi-centered Study of Low-dose Everolimus Plus Cisplatin and Weekly 24-Hour Infusion of High-dose 5-Fluorouracil and Leucovorin as First-line Treatment for Patients with Advanced Gastric Cancer. Oncology. 2014 Jul 4;87(2):104-113. (impact factor: 2.17)

17. Lee JH, Lin YL (Co-first-author), Chen HY, Chang YC, Yu CJ, Shih JY, Chen KY, Yang PC, Yang JC. BIM deletion polymorphism predicts systemic treatment outcome in advanced non-small cell lung cancer. J Thorac Oncol. 2014 Sep;9(9):1385-92 (impact factor: 4.473)

18. Wang CC, Liang JT, Tsai CL, Chen YH, Lin YL, Shun CT, Cheng JC. Neoadjuvant Bevacizumab and Chemoradiotherapy in Locally Advanced Rectal Cancer: Early Outcome and Technical Impact on Toxicity. World Journal of Surgical Oncology 2014, 12:329

19. Tsai JH, Lin YL, Cheng YC, Chen CC, Lin LI, Tseng LH, Cheng ML, Liau JY, and Jeng YM. Aberrant expression of annexin A10 is closely related to gastric phenotype in serrated pathway to colorectal carcinoma. Mod Pathol. 2015 Feb;28(2):268-78. (impact factor: 5.25) IF=6.364; 5/76 Pathology

20. Liang YH, Lin YL (Co-first author) , Tsai JH, Liau JY, Liang JT, Lin BR, Hung JS, Tseng LH, Lin LI, Chang YL, Yeh KH, Cheng AL. Cetuximab Might Be Not Only Unfavorable But Also Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations. Anticancer Res. 2015 Jul;35(7):4207-14.

21. Lin BR, Lin YL, Lai HS, Lee PH, Chang KJ, Liang JT. Overall Survival of Stage III Colon Cancer with Only One Lymph Node Metastasis Is Independently Predicted by Preoperative Carcinoembryonic Antigen Level and Lymph Node Sampling Status, but Not by Adjuvant Chemotherapy. Plos One 2015 Sep 18;10(9):e0137053

22. Tsai JH, Cheng YC, Chen CC, Lin YL, Lin LI, Cheng ML, Liau JY, and Jeng YM. Traditional serrated adenoma with BRAF mutation is associated with synchronous/metachronous BRAF mutated serrated lesions. Histopathology.

5

2015 (Accepted). IF: 3.4323. Liau JY, Tsai JH, Lin YL, Tseng LH, Lin LI, Yeh KH, and Jeng YM. Frequent

BRAF mutation in early-onset colorectal cancer in Taiwan: associated with distinct clinicopathological and molecular features and poor clinical outcome. Journal of Clinical Pathology. 2015 (accepted)

24. Yang PC, Lin BR, Chen YC, Lin YL, Lai HS, Huang KW, Jin-Tung Liang. Local Control by Radiofrequency Thermal Ablation May Increase Overall Survival in Patients with Refractory Liver Metastases of Colorectal Cancer. Medicine 2016, (in revision)

25. Lin YL , Liau JY, Tsai JH, Tseng LH, Lin LI, Liang JT, Lin BR, Hung JS, Chang YL, Yeh KH, Cheng AL. BRAF mutation may have different prognostic implications in early-stage compared with late-stage colorectal cancer. (preperation)

INTERNATIONAL MEETING ABSTRACTS

1. Lin CC, Lin ZZ, Lin YL, Yu CJ, Shih JY, Chen KY, Ho CC, Liao WY, Yang CH James. A phase I dose defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation. ASCO meeting 2012. Proc Am Soc Clin Oncol 2012 (abstract #96402)

2. Yeh KH, Kao CH, Fan HF, Cheng CJ, Lin YL , Cheng AL. AUY922, a heat shock protein 90 inhibitor, plus 5-fluorouracil inhibits tumors synergistically in gastric cancer MKN45 xenograft via down regulation of multiple pivotal growth factor receptors and oncoproteins. AACR 2012 (abstract #2767)

3. Lee JH, Lin YL(Co-first author), Chen HY, Chang YC, Yu CJ, Shih JY, Chen KY, Yang PC, Yang CH. BIM deletion polymorphism to predict systemic treatment outcome in advanced non-small cell lung cancer. ASCO meeting 2013. J Clin Oncol 31, 2013 (suppl; abstr 8055)

4. Chen KH, Chen HM, Lin YL, Lai MS, Cheng AL, Yeh KH. Primary tumor site is a useful predictor for cetuximab efficacy in KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer. ASCO meeting 2015.

5. Hsieh RK, Lin YL, Tang CH. Strong Opioid Prescription in advanced cancer patients in their final year of life in Taiwan: A Population-based analysis using National Health Insurance Database. ESMO 2015.

6. Chiang NJ, Yeh KH, Chiu CF, Chen JS, Yen CC, Lee KD, Lin YL, Bai LY, Chen MH, Lin TH, Yang YS, Rau KM, Hsiao HH, Shan YS, Chen LT, On behalf of TCOG, NICR, NHRI, Taiwan. Phase II trial of AUY922, a novel heat

6

shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) failed to imatinib and sunitinib therapy. ASCO GI 2016.

INTERNATIONAL MEETING ABSTRACTS

1. Lin CC, Lin ZZ, Lin YL, Yu CJ, Shih JY, Chen KY, Ho CC, Liao WY, Yang CH James. A phase I dose defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation. ASCO meeting 2012. Proc Am Soc Clin Oncol 2012 (abstract #96402)

2. Yeh KH, Kao CH, Fan HF, Cheng CJ, Lin YL , Cheng AL. AUY922, a heat shock protein 90 inhibitor, plus 5-fluorouracil inhibits tumors synergistically in gastric cancer MKN45 xenograft via down regulation of multiple pivotal growth factor receptors and oncoproteins. AACR 2012 (abstract #2767)

3. Lee JH, Lin YL(Co-first author), Chen HY, Chang YC, Yu CJ, Shih JY, Chen KY, Yang PC, Yang CH. BIM deletion polymorphism to predict systemic treatment outcome in advanced non-small cell lung cancer. ASCO meeting 2013. J Clin Oncol 31, 2013 (suppl; abstr 8055)

4. Chen KH, Chen HM, Lin YL, Lai MS, Cheng AL, Yeh KH. Primary tumor site is a useful predictor for cetuximab efficacy in KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer. ASCO meeting 2015.

GRANTS

1. Center of Excellence for Cancer Research, National Taiwan University Hospital, 4-year (2010-2013) grants, granted by Ministry of Health and Welfare, Executive Yuan, Taiwan

2. Center of Excellence for Cancer Research, National Taiwan University Hospital, 4-year (2014-2017) grants, granted by Ministry of Health and Welfare, Executive Yuan, Taiwan

7